144 related articles for article (PubMed ID: 14699908)
1. Enzymatic and binding activities of 5 alpha-reductase and androgen receptors in hamster prostate.
Cabeza M; Bratoeff E; Heuze I; Ramírez E; Sánchez M; Flores E
Proc West Pharmacol Soc; 2003; 46():128-31. PubMed ID: 14699908
[No Abstract] [Full Text] [Related]
2. Effect of beta-sitosterol as inhibitor of 5 alpha-reductase in hamster prostate.
Cabeza M; Bratoeff E; Heuze I; Ramírez E; Sánchez M; Flores E
Proc West Pharmacol Soc; 2003; 46():153-5. PubMed ID: 14699915
[No Abstract] [Full Text] [Related]
3. Molecular interactions of progesterone derivatives with 5 alpha-reductase types 1 and 2 and androgen receptors.
Bratoeff E; García P; Heuze Y; Soriano J; Mejía A; Labastida AM; Valencia N; Cabeza M
Steroids; 2010 Jul; 75(7):499-505. PubMed ID: 20359488
[TBL] [Abstract][Full Text] [Related]
4. Aromatic esters of progesterone as 5alpha-reductase and prostate growth inhibitors.
Bratoeff E; Segura T; Recillas S; Carrizales E; Palacios A; Heuze I; Cabeza M
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):655-62. PubMed ID: 18825535
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
6. 5 alpha-reductase inhibition by a new synthetic steroid (PM-9) in cultures of Penicillium crustosum.
Cabeza M; Quiroz A; Bratoeff E; García G; Ramírez E; Flores E
Proc West Pharmacol Soc; 2002; 45():164-5. PubMed ID: 12434569
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptors in benign and malignant prostatic tissue.
Lakey WH; Bruchovsky N; Callaway T; Comeau T; Lieskovsky G; Rennie P; Shnitka T; Wilkin P
Trans Am Assoc Genitourin Surg; 1979; 71():19-22. PubMed ID: 94714
[TBL] [Abstract][Full Text] [Related]
8. [Hormonal therapy for benign prostatic hyperplasia].
Sakai H; Kanetake H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
[No Abstract] [Full Text] [Related]
9. New 5alpha-reductase inhibitors: in vitro and in vivo effects.
Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; Ramírez E; Naranjo-Rodríguez E
Steroids; 2005 Mar; 70(3):217-24. PubMed ID: 15763601
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor binding and antiandrogenic activity of some 4,5-secoandrostanes and ring B cyclopropanoandrostanes.
Stárka L; Hampl R; Kasal A; Kohout L
J Steroid Biochem; 1982 Sep; 17(3):331-4. PubMed ID: 6215537
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the regulation of prostatic oxytocin by gonadal steroids in the rat.
Jenkin L; Nicholson HD
J Androl; 1999; 20(1):80-7. PubMed ID: 10100477
[TBL] [Abstract][Full Text] [Related]
12. New progesterone esters as antagonists of androgen receptors.
Cabeza M; Quiroz A; Bratoeff E; Heuze I; Ramírez E; Flores E
Proc West Pharmacol Soc; 2002; 45():166-7. PubMed ID: 12434570
[No Abstract] [Full Text] [Related]
13. The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review.
Wang LG; Mencher SK; McCarron JP; Ferrari AC
Oncol Rep; 2004 Jun; 11(6):1325-9. PubMed ID: 15138573
[TBL] [Abstract][Full Text] [Related]
14. Brain androgen-inducible aromatase is critical for adolescent organization of environment-specific social interaction in male rats.
Kellogg CK; Lundin A
Horm Behav; 1999 Apr; 35(2):155-62. PubMed ID: 10202123
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride.
Makridakis N; Reichardt JK
J Mol Endocrinol; 2005 Jun; 34(3):617-23. PubMed ID: 15956333
[TBL] [Abstract][Full Text] [Related]
16. 5alpha-reductase inhibitors.
Rittmaster RS
J Androl; 1997; 18(6):582-7. PubMed ID: 9432130
[No Abstract] [Full Text] [Related]
17. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.
Suzuki K; Nishiyama T; Hara N; Yamana K; Takahashi K; Labrie F
Prostate Cancer Prostatic Dis; 2007; 10(3):301-6. PubMed ID: 17387321
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
19. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and pharmacological evaluation of new steroidal 5 alpha-reductase inhibitors.
Bratoeff E; Cabeza M; Flores E; Ramirez E; Quiroz A; Heuze I
Proc West Pharmacol Soc; 2002; 45():187-90. PubMed ID: 12434577
[No Abstract] [Full Text] [Related]
[Next] [New Search]
